In a 36-week study, semaglutide was found to aid in weight loss for people with schizophrenia without worsening psychotic ...

We have recently begun acquiring a new position in Novo Nordisk. Click here for our investment thesis on NVO stock.

Diabetic weight-loss medications are effective for people with schizophrenia without affecting psychotic symptoms, University ...

Treatment should be stopped if nonarteritic anterior ischemic optic neuropathy, which can cause vision loss, is diagnosed.

A study, which was published in The New England Journal of Medicine, found that tirzepatide (Zepbound) is more effective for ...

Pharmacovigilance Risk Assessment Committee (PRAC) has concluded its review of semaglutide-containing medicines, confirming a ...

This initial report lacked some information that will become available at the time of full study publication. “Additional analyses of the early MACE separation for semaglutide versus placebo by ...

Novo Nordisk’s drugs are being linked to an eye condition that can cause vision loss, while health tech companies made CNBC’s ...

An international clinical trial, led in the UK by Swansea’s Joint Clinical Research Facility (JCRF), has found that ...

A Cleveland Clinic study shows that semaglutide and tirzepatide—injectable GLP-1 drugs for obesity—produce smaller weight ...

Data brief analyzes patenting and pricing practices for blockbuster drugs Eliquis and semaglutide medications (Ozempic, Rybelsus, Wegovy), continuing the acclaimed Overpatented, Overpriced series that ...

European Medicines Agency (EMA)'s safety committee (PRAC) has concluded its review of medicines containing semaglutide ...